Study finds why asthma drugs help some children but not others

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
Pulmonology Advisor

FDA Greenlights Exdensur for Severe Eosinophilic Asthma

The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.
Medical Dialogues

FDA Approves Depemokimab-ulaa as First Twice-Yearly Biologic for Severe Eosinophilic Asthma

Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...